OCGN

Ocugen Inc

OCGN, USA

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

https://www.ocugen.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
OCGN
stock
OCGN

How The Latest Analyst Shifts Are Reshaping Ocugenโ€™s Story and Valuation Yahoo Finance

Read more โ†’
OCGN
stock
OCGN

Ocugen Inc. Stock Falls Friday, Underperforms Market ๅฏŒ้€”็‰›็‰›

Read more โ†’

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$9

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

117.02

Low โ‰ค 1

High โ‰ฅ 3

Return on Equity (ROE)

-

Very Low

-567.53 %

Low โ‰ค 5%

High โ‰ฅ 25%

Return on Assets (ROA)

-

Very Low

-34.81 %

Low โ‰ค 2%

High โ‰ฅ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-742.41 %

Low โ‰ค 5%

High โ‰ฅ 15%

Debt to Equity

-

Very Low

15.30

Low โ‰ฅ 1

High โ‰ค 0.3

Investors

* Institutions hold a combined 20.97% of the total shares of Ocugen Inc

1.

Vanguard Group Inc

(4.7302%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(2.843%)

since

2025/07/31

3.

BlackRock Inc

(1.7902%)

since

2025/06/30

4.

Millennium Management LLC

(1.6199%)

since

2025/06/30

5.

GMT Capital Corp

(1.33%)

since

2025/06/30

6.

Geode Capital Management, LLC

(1.1168%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9945%)

since

2025/07/31

8.

GSA Capital Partners LLP

(0.5535%)

since

2025/06/30

9.

Cubist Systematic Strategies, LLC

(0.5337%)

since

2025/06/30

10.

Fidelity Extended Market Index

(0.5035%)

since

2025/07/31

11.

State Street Corp

(0.4287%)

since

2025/06/30

12.

Rinkey Investments

(0.3775%)

since

2025/06/30

13.

Jane Street Group LLC

(0.3714%)

since

2025/06/30

14.

CI Private Wealth LLC

(0.2882%)

since

2025/06/30

15.

Vanguard Health Care ETF

(0.2863%)

since

2025/07/31

16.

Goldman Sachs Group Inc

(0.284%)

since

2025/06/30

17.

UBS Group AG

(0.2095%)

since

2025/06/30

18.

SummitTX Capital, L.P

(0.2047%)

since

2025/06/30

19.

Extended Equity Market Fund K

(0.2023%)

since

2025/06/30

20.

Morgan Stanley - Brokerage Accounts

(0.1959%)

since

2025/06/30

21.

Citadel Advisors Llc

(0.1928%)

since

2025/06/30

22.

Northern Trust Corp

(0.1812%)

since

2025/06/30

23.

Fidelity Total Market Index

(0.166%)

since

2025/07/31

24.

Susquehanna International Group, LLP

(0.165%)

since

2025/06/30

25.

Brevan Howard Capital Management LP

(0.1648%)

since

2025/06/30

26.

Royal Bank of Canada

(0.1643%)

since

2025/06/30

27.

Fidelity Series Total Market Index

(0.1333%)

since

2025/07/31

28.

Spartan Extended Market Index Pool F

(0.113%)

since

2025/07/31

29.

Galileo - Biotech Innovation Fund S USD

(0.1025%)

since

2025/02/28

30.

NT Ext Equity Mkt Idx Fd - L

(0.0953%)

since

2025/06/30

31.

Northern Trust Extended Eq Market Idx

(0.0953%)

since

2025/06/30

32.

NT Ext Equity Mkt Idx Fd - NL

(0.0819%)

since

2025/06/30

33.

Spartan Total Market Index Pool G

(0.0663%)

since

2025/07/31

34.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0636%)

since

2025/06/30

35.

Vanguard Balanced Index Inv

(0.0601%)

since

2025/07/31

36.

Fidelity Nasdaq Composite Index

(0.0586%)

since

2025/07/31

37.

Schwab Total Stock Market Index

(0.0545%)

since

2025/07/31

38.

iShares Ageing Population ETF USD Acc

(0.0504%)

since

2025/08/31

39.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0471%)

since

2025/07/31

40.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0471%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.056

Latest Release

Date

2025-09-30

EPS Actual

-0.07

EPS Estimate

-0.056

EPS Difference

-0.014

Surprise Percent

-25%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.